Press Release

United Kingdom Liquid Biopsy Market to be Dominated by Oncological Application Through 2028

Increasing prevalence of cancer and PCR technologies are expected to drive the United Kingdom Liquid Biopsy Market in the forecast period, 2024-2028.

According to TechSci Research report, “United Kingdom Liquid Biopsy Market – By Region, Competition Forecast and Opportunities, 2018-2028, the United Kingdom Liquid Biopsy Market is anticipated to grow at a significant rate in the forecast period of 2024-2028. The Liquid Biopsy Market in the United Kingdom is witnessing significant growth, driven by the increasing prevalence of cancer and the need for early cancer detection. One of the key factors driving the growth of the liquid biopsy market in the United Kingdom is the increasing availability and adoption of cutting-edge technologies. Next-generation sequencing (NGS), for instance, has emerged as a powerful tool in liquid biopsy, enabling the detection and analysis of genetic alterations and biomarkers associated with various diseases. NGS allows for the identification of minute quantities of circulating tumor DNA (ctDNA) in the bloodstream, providing valuable information about tumor mutations and assisting in treatment decision-making. The incorporation of NGS into liquid biopsy workflows has significantly enhanced the sensitivity and specificity of disease detection, making it a game-changer in personalized medicine. The increasing collaboration between academic institutions, research organizations, and healthcare providers has also contributed to the growth of the liquid biopsy market in the United Kingdom. Such collaborations foster knowledge exchange, accelerate technology development, and promote the translation of research findings into clinical practice, thereby augmenting the growth of the United Kingdom Liquid Biopsy Market in the forecast period. However, the high cost of liquid biopsy and the lack of skilled professionals can be barriers to access for some individuals, particularly those from low-income backgrounds, which may hamper the market's growth in the forecast period.

Browse over XX market data Figures spread through XX Pages and an in-depth TOC on United Kingdom Liquid Biopsy Market

The United Kingdom Liquid Biopsy Market is segmented into Offering, Technology, Workflow, Sample, Circulating Biomarker, Application, End User, Region and Competitive Landscape.

Based on Offering, the market is divided into Testing Service, Kits, Platform, and Other Consumables. The Testing Service segment is expected to witness a rise over the forecast period. This is attributed to the prevalence of cancer cases and rising awareness regarding cancer diagnostics, which is anticipated to support market growth in the future.

Based on Technology, the market is divided into Polymerase Chain Reactions, Next Generation Sequencing, and Others. Next Generation Sequencing is expected to witness a rise over the forecast period. This is attributed to its better results in cancer detection.

Based on Workflow, the market is divided into Sample Preparation, Library Preparation, Sequencing, and Data Analysis & Management. Data Analysis & Management is expected to witness a rise over the forecast period. This is attributed to drilling out the root cause of disease that helps in the treatment prescription.

Based on Sample, the market is divided into Blood, Urine, Saliva, and Others. Blood segment is expected to witness a rise over the forecast period. This is attributed to the detection of cancerous tumors and cancer cell DNA from the blood sample.

Based on Circulating Biomarker, the market is divided into Circulating Tumor Cells (CTCs), Cell Free Nucleic Acids, Exosomes & Extracellular Vesicles, and Others. Circulating Tumor Cells (CTCs) are expected to witness a rise over the forecast period. The market demand is being driven by the rising incidence of cancer and the development of ctDNA-based liquid biopsy analysis, which can predict tumor progression.

Based on Application, the market is divided into Oncological and Non-Oncological. Oncological Liquid Biopsy is expected to witness a rise over the forecast period. This is attributed to the detection of tumor cells by incorporating liquid biopsy.

Based on End User, the market is divided into Clinical Laboratories, Academic & Research Institutes, and Pharmaceutical & Biotechnology Companies. Clinical Laboratories are expected to witness a rise over the forecast period. This can be attributed to the availability of both inpatient and outpatient medication facilities and certified healthcare professionals leading to the growth of the United Kingdom Liquid Biopsy market.

Major companies operating in United Kingdom Liquid Biopsy Market are:

  • F. Hoffmann-La Roche AG
  • Thermo Fisher Scientific, Inc
  • PerkinElmer Inc.
  • Illumina, Inc.
  • QIAGEN NV
  • Dxcover Limited
  • Abcodia Ltd
  • Sysmex Corporation
  • Bio-Rad Laboratories, Inc.

Download Free Sample Report
Customers can also request 10% free customization in this report.

The United Kingdom Liquid Biopsy Market is poised for significant growth in the coming years due to the escalating prevalence of cancer among the population in the nation. The burgeoning technological advancements in the medical diagnostics industry and the rising number of hospitals in the country will drive a notable market segment in the United Kingdom. Furthermore, the increasing healthcare investments and government initiatives for research and innovation will bolster the market's growth trajectory, which is anticipated to continue flourishing until 2028," stated Mr. Karan Chechi, Research Director at TechSci Research, a research-based global management consulting firm.

“United Kingdom Liquid Biopsy Market By Offering (Testing Service, Kits, Platform, Other consumables), By Technology (Polymerase Chain Reactions (PCR), Next Generation Sequencing (NGS), Others), By Workflow (Sample Preparation, Library Preparation, Sequencing, Data Analysis & Management), By Sample (Blood, Urine, Saliva, Others), By Circulating Biomarkers (Circulating Tumor Cells (CTCs), Cell-free Nucleic Acids, Exosomes & Extracellular Vesicles, Others), By Application (Oncological and Non-oncological), By End User (Clinical Laboratories, Academic & Research Institutes, Pharmaceutical & Biotechnology Companies), By Region, Competition Forecast & Opportunities, 2018-2028F,” has evaluated the future growth potential of United Kingdom Liquid Biopsy Market and provides statistics & information on market size, structure, and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in United Kingdom Liquid Biopsy Market.

Contact

Mr. Ken Mathews

708 Third Avenue,

Manhattan, NY,

New York – 10017

Tel: +1-646-360-1656

Email: [email protected]

Web:  https://www.techsciresearch.com

Relevant News